The Foundation for Children with Atypical HUS

FDA grants Orphan Drug Designation to LFB’s « Complement Factor H »

In December 2009, the Food and Drug Administration (FDA) granted LFB (Laboratoire
français du Fractionnement et des Biotechnologies) with the Orphan Designation for its
Complement Factor H, a human plasma-derived product, currently in pre-clinical
development.
The designated orphan indication is for the "Treatment of atypical Hemolytic Uremic
Syndrome (aHUS) associated with an inherited abnormality of the complement system".
For more information, please visit www.lfb.fr

Isn't it a great news? :)))

Views: 35

Tags: atypical, factor, h, hus

Comment

You need to be a member of The Foundation for Children with Atypical HUS to add comments!

Join The Foundation for Children with Atypical HUS

Comment by Linda Burke on March 1, 2010 at 3:12pm
No way! Don't be at all sorry, Zofia .... by putting this exciting info in your front page Blog you're helping to raise awareness of something very valuable 'in the pipeline'. I can't wait for someone to hear about the next steps for this wonderful development. I can understand LBF's need to keep things hush-hush because of the proprietary nature, but I'm just so curious to learn the details! Thanks in advance for keeping an eye out for any more news on this front- we'd appreciate it an update whenever possible. With appreciation, Linda
Comment by Cheryl Biermann on March 1, 2010 at 9:59am
Way to go Zofia, it's amazing you found this information, excellent! Let us know any further developments. Thanks.
Comment by Zofia on March 1, 2010 at 4:19am
Sorry Linda :). Next time I’ll check our page better before writing something. But I’ll definitely try to find some more info about that treatment.
Comment by Linda Burke on February 28, 2010 at 1:58pm
Thanks Zofia, for raising awareness in your blog and bringing this to everyone's attention. In the 'Current Research' Forum, Joy Lewis has a 27kb pdf version filed in her Feb 14th post. Thanks to Mireya in Spain who alerted Joy to the information for posting in the Current Research Forum.
Zofia, this IS a most interesting trail to follow - as yet we have uncovered no further leads but we can't wait to find out any further info you discover on the human-derived Factor H product. Thanks so much for your blog!

WELCOME - Friends, Family Members, Patients, and Researchers - JOIN US!

The Foundation for Children with Atypical HUS encourages patients and investigators to share information and explore options/resources as we work together to gain insight into this rare complement disorder. By increasing contact opportunities with researchers and medical personnel interested in helping the aHUS community, our stories foster a better understanding of atypical hemolytic uremic syndrome.

Sharing information, inspiration and support for one another, we seek to gather together people and knowledge as we strive to improve the lives of patients and families dealing with a diagnosis of aHUS.


NEW DIAGNOSIS OF aHUS?
Be proactive! Get the medical basics of aHUS, what lab values to monitor, and areas of concern...check out the "aHUS Bootcamp" and "About aHUS" tabs at the top of this page!
If your doctor has never treated a case of aHUS, please print out our 'Doc to Doc Registry' and ask him/her to contact a physician versed in the complexities of aHUS and new options for 2011 genetic testing and treatment.

************************

NOTE: Our 'Send a Message" function on each Member's page allows for private discussion of personal content. As with any social network, be cautious about giving personal contact information (home email info, phone number) until you have an established relationship with another person, organization, or associated website.

 

Did you know...

CFH (Serum Complement Factor H) is a regulatory protein. The secreted protein product of CFH consists of 20 repetitive units named "short consensus repeats" or SCRs (each approximately 60 amino acids). In patients with aHUS the last 5 "pearls" in the twenty pearl strand protein, SCR16 - SCR20, should bind to protect cells but do not- they are defective in one or more of the last 5 SCR locations. If they cannot bind or stick to the kidney to protect that tissue, the platelets clump into clots that affect the glomeruli of the kidney -potentially causing acute renal failure.
  
• • • • • • • • • • • •
  
It is estimated that there are about 300 cases of aHUS in the U.S., and it is most common with young children. The condition is life threatening and either can be chronic or can recur at intervals.
  
more factoids...

Help us fight the battle

Your tax-deductible purchase of one or more bracelets will directly fund research to help end the tragedy and heartbreak that aHUS families live with every day. Each bracelet has an appraised value of $825, but your purchase price is only $295.

  

  
Or you can donate a specific dollar amount-every dollar will help the Foundation for Children with atypical HUS atypicalHUS.50megs.com


Donations may be made via credit card or Paypal. If you prefer, checks made payable to The Foundation for Children with Atypical HUS may be mailed to:
Atypical aHUS Foundation
19 Olde Colony Lane
Cape Elizabeth, ME 04107
For pearl bracelet orders, please allow extra time for processing checks.



Badge

Loading…

© 2012   Created by ALPHA MARKETING.   Powered by

Badges  |  Report an Issue  |  Terms of Service